Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04147260 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04147260: Completed Phase 1 study, sponsored by Boehringer Ingelheim.
NCT04147260 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04147260, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
To evaluate the photosensitivity potential of BI 730357
Primary Outcome
Photosensitivity index (PI) under condition 1 (C1)(i.e., under full range solar UVB/UVA (290 to 400 nm, UBV content \~10%), simulating midday summer outdoor sun exposure (assessed in μw/cm2)), was defined as ratio of the precise Minimum erythema dose (MED)baseline to MEDon-drug at each respective post irradiation time point (i.e. 24 hours)(i.e., MEDon-drug\[millijoules (mJ)\]/MEDbaseline\[mJ\]) and was hence unitless. MED was defined as lowest dose that produced uniform redness (C1) (assessed i
Interventions
- DRUG Ciprofloxacin
- DRUG BI 730357
- DRUG Placebo to match BI 730357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2020-09-09 |
| Phase | Phase 1 |
What the finished NCT04147260 record still lists
NCT04147260 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 3 interventions - of which Ciprofloxacin is the first listed.
NCT04147260 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04147260 about?
NCT04147260 is a clinical study titled "Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin". To evaluate the photosensitivity potential of BI 730357
What is the current status of trial NCT04147260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2019-11-06. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT04147260?
The interventions under investigation include: Ciprofloxacin (DRUG), BI 730357 (DRUG), Placebo to match BI 730357 (DRUG).
Who is sponsoring clinical trial NCT04147260?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04147260's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI